Hemogenyx Pharmaceuticals

HEMO · Main Market · Health Care · mcap £48m · 735.0p

Beta Briefing, track record and bull & bear case are not ready for Hemogenyx Pharmaceuticals yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 38 companies are already wired into a briefing: browse them.

Financials · LTM to 30 Jun 26

Source: results 28 Sep 26 ↗

Revenue: £0k
Operating profit: −£7.0m
Net income: −£11.3m
Free cash flow: −£2.2m
Net cash: £4.6m
Market cap: £50.7m
EV / EBIT: –
FCF yield: −4.4%
Price / book: –

Latest half-year · H1 26 vs H1 25 results 28 Sep 26 ↗

Net income: −£6.6m
Cash from operations: −£1.7m

Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.

Income statement Cash flow Balance sheet

Annual Half-yearly

Latest report: H1 26 (six months to 30 Jun 26), published 28 Sep 26 · read the results ↗

£m unless stated · newest first · italic = calculated (LTM, H2 = FY − H1) · hover a value for its source

	LTM Jun 26	FY 25	FY 24
Revenue	–	0.0	0.0
Operating profit	–	(7.0)	(5.4)
Depreciation (owned assets)	(0.6)	(0.6)	(0.6)
Share-based payments	5.6	0.1	0.3
Fair value gains / losses	–	(2.3)	0.0
Finance costs	–	(0.2)	(0.3)
Profit before tax	(11.3)	(9.8)	(5.6)
Tax	–	0.0	0.0
Net income (owners)	(11.3)	(9.8)	(5.6)
EPS basic	–	(170.6p)	(181.1p)
EPS diluted	–	(170.6p)	(181.1p)

	H1 26	vs H1 25	H2 25	H1 25
Depreciation (owned assets)	0.1	−53%	(0.7)	0.1
Depreciation (right-of-use)	0.2	−4%	–	0.2
Share-based payments	5.5	n/m	0.1	0.0
Profit before tax	(6.6)	n/m	(4.8)	(5.0)
Net income (owners)	(6.6)	n/m	(4.8)	(5.0)

	LTM Jun 26	FY 25	FY 24
Cash from operations	(1.6)	(3.4)	(4.1)
Capex (PP&E)	0.0	(0.0)	(0.0)
Lease principal paid	(0.6)	(0.6)	(0.6)
Shares issued	8.5	5.5	3.7

	H1 26	vs H1 25	H2 25	H1 25
Cash from operations	(1.7)	n/m	0.1	(3.5)
Capex (PP&E)	0.0	n/m	0.0	(0.0)
Lease principal paid	(0.3)	−8%	(0.3)	(0.3)
Shares issued	5.0	+149%	3.5	2.0

	Latest Jun 26	FY 25	FY 24
Other intangibles	–	0.2	0.5
Property, plant & equipment	–	0.4	0.8
Trade receivables	–	0.4	0.7
Cash	4.6	1.6	0.2
Current assets	–	2.0	0.8
Total assets	–	4.2	4.2
Trade payables	–	1.0	0.7
Lease liabilities, current	–	0.4	0.4
Current liabilities	–	1.5	1.2
Lease liabilities, non-current	–	1.6	2.2
Total liabilities	–	3.0	3.4
Non-controlling interests	–	(0.1)	(0.0)
Total equity	–	1.1	0.9

	H1 26	H2 25	H1 25	H2 24
Other intangibles	–	0.2	–	0.5
Property, plant & equipment	–	0.4	–	0.8
Trade receivables	–	0.4	–	0.7
Cash	4.6	1.6	0.2	0.2
Current assets	–	2.0	–	0.8
Total assets	–	4.2	–	4.2
Trade payables	–	1.0	–	0.7
Lease liabilities, current	–	0.4	–	0.4
Current liabilities	–	1.5	–	1.2
Lease liabilities, non-current	–	1.6	–	2.2
Total liabilities	–	3.0	–	3.4
Non-controlling interests	–	(0.1)	–	(0.0)
Total equity	–	1.1	–	0.9

Line items extracted automatically from each results announcement; when a later report restates a period, the later figure is shown. LTM and H2 are calculated from reported periods. Check the source before relying on a figure.

Company filings. Not investment advice.